Omnicell, Inc. (NASDAQ:OMCL) Shares Sold by State of Alaska Department of Revenue

State of Alaska Department of Revenue decreased its stake in shares of Omnicell, Inc. (NASDAQ:OMCL) by 2.5% during the 1st quarter, Holdings Channel reports. The institutional investor owned 25,664 shares of the company’s stock after selling 659 shares during the period. State of Alaska Department of Revenue’s holdings in Omnicell were worth $897,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of OMCL. Lazard Asset Management LLC increased its stake in Omnicell by 81.6% during the 4th quarter. Lazard Asset Management LLC now owns 1,641,817 shares of the company’s stock valued at $73,093,000 after buying an additional 737,536 shares during the period. Toronto Dominion Bank acquired a new position in Omnicell during the 4th quarter valued at about $30,637,000. Dimensional Fund Advisors LP increased its stake in Omnicell by 31.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,642,626 shares of the company’s stock valued at $73,127,000 after buying an additional 394,820 shares during the period. Victory Capital Management Inc. increased its stake in Omnicell by 32.9% during the 4th quarter. Victory Capital Management Inc. now owns 1,526,309 shares of the company’s stock valued at $67,951,000 after buying an additional 377,883 shares during the period. Finally, Oberweis Asset Management Inc. acquired a new position in Omnicell during the 4th quarter valued at about $14,834,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on OMCL shares. Wall Street Zen raised shares of Omnicell from a “hold” rating to a “buy” rating in a research note on Tuesday, May 20th. Bank of America lifted their price objective on shares of Omnicell from $30.00 to $34.00 and gave the stock a “neutral” rating in a research note on Friday, May 23rd. Piper Sandler reaffirmed an “overweight” rating on shares of Omnicell in a research note on Friday, May 23rd. JPMorgan Chase & Co. lowered their price objective on shares of Omnicell from $44.00 to $36.00 and set a “neutral” rating on the stock in a research note on Thursday, March 20th. Finally, Wells Fargo & Company reaffirmed an “overweight” rating and issued a $37.00 price objective (up previously from $35.00) on shares of Omnicell in a research note on Friday, May 23rd. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $44.83.

Omnicell Stock Performance

Shares of OMCL opened at $28.84 on Friday. Omnicell, Inc. has a 12-month low of $22.66 and a 12-month high of $55.75. The firm’s 50 day moving average is $29.27 and its 200-day moving average is $35.94. The stock has a market capitalization of $1.35 billion, a P/E ratio of 62.70 and a beta of 0.78. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.38 and a quick ratio of 1.23.

Omnicell (NASDAQ:OMCL) last announced its earnings results on Tuesday, May 6th. The company reported $0.26 EPS for the quarter, topping the consensus estimate of $0.16 by $0.10. Omnicell had a net margin of 1.87% and a return on equity of 4.60%. The company had revenue of $269.67 million during the quarter, compared to analysts’ expectations of $260.18 million. During the same period last year, the company posted $0.03 earnings per share. The business’s revenue for the quarter was up 9.5% on a year-over-year basis. Equities research analysts anticipate that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.